PD-1, PD-L1 (B7-H1) and Tumor-Site Immune Modulation Therapy: The Historical Perspective

The current success of targeted inhibition against cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and Programmed Death 1/Programmed Death Ligand 1 (PD-1/PD-L1, herein collectively referred to as PD) pathways is hailed as a cancer immunotherapy breakthrough. PD-L1, known also as B7 homolog 1 (B...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Jun, Yuan, Ruirong, Song, Wenru, Sun, Jingwei, Liu, Delong, Li, Zihai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5267378/
https://www.ncbi.nlm.nih.gov/pubmed/28122590
http://dx.doi.org/10.1186/s13045-017-0403-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5267378/
https://www.ncbi.nlm.nih.gov/pubmed/28122590
http://dx.doi.org/10.1186/s13045-017-0403-5

Ejemplares similares